• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Silexion Therapeutics Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    9/26/25 4:05:44 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SLXN alert in real time by email
    false000202241600-0000000972NASDAQNASDAQ00020224162025-09-262025-09-260002022416slxn:OrdinarySharesParValue00135PerShareMember2025-09-262025-09-260002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf155250PerShareMember2025-09-262025-09-26



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): September 26, 2025

    Silexion Therapeutics Corp
    (Exact name of registrant as specified in its charter)

    Cayman Islands
     
    001-42253
     
    N/A
    (State or other jurisdiction
     
    (Commission File Number)
     
    (I.R.S. Employer
    of incorporation)
     

     
    Identification No.)

     

    12 Abba Hillel Road

    Ramat-Gan, Israel

     
    5250606
    (Address of principal executive offices)
     
    (Zip Code)

    +972-3-7564999
    (Registrant’s telephone number, including area code)

    N/A
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange on which registered
    Ordinary Shares, par value $0.0135 per share
     
    SLXN
     
    The Nasdaq Stock Market LLC
    Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share
     
    SLXNW
     
    The Nasdaq Stock Market LLC


    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 1.01 Entry into a Material Definitive Agreement.
     
    On September 26, 2025, Silexion Therapeutics Corp (the “Company”), entered into an At The Market Offering Agreement, (the “Offering Agreement”), with H.C. Wainwright & Co., LLC, as agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time through Wainwright ordinary shares of the Company, par value $0.0135 per share (the “Ordinary Shares”), having an aggregate offering price of up to $13.17 million (the “Shares”).
     
    Any sale of the Shares under the Offering Agreement will be made pursuant to a shelf registration statement on Form S-3 and the related prospectus to be filed by the Company with the Securities and Exchange Commission (the “SEC”), on September 26, 2025, after such Registration Statement is declared effective by the SEC.
     
    Pursuant to the Offering Agreement, Wainwright may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”) including sales made by means of ordinary brokers’ transactions, including on The Nasdaq Capital Market, at market prices or as otherwise permitted by law. Wainwright will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Shares pursuant to the Offering Agreement from time to time, based upon instructions from the Company, including any price or size limits or other customary parameters or conditions the Company may impose.
     
    The Company is not obligated to make any sales of the Shares under the Offering Agreement. The offering of Shares pursuant to the Offering Agreement will terminate upon the earliest of (a) the sale of all of the Shares subject to the Offering Agreement and (b) the termination of the Offering Agreement by Wainwright or the Company, as permitted therein.
     
    The Company will pay to Wainwright a cash commission of 3% of the gross sales price of any Ordinary Shares sold under the Offering Agreement and has agreed to provide Wainwright with customary indemnification and contribution rights. The Company will also reimburse Wainwright for certain specified expenses in connection with entering into the Offering Agreement.
     
    The Offering Agreement contains customary representations and warranties and conditions to the sale of the Shares pursuant thereto.
     
    The foregoing description of the Offering Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference into this Item 1.01.
     
    This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Shares discussed herein, nor shall there be any offer, solicitation, or sale of securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
     
    Item 9.01. Financial Statements and Exhibits.
     
    (d) Exhibits
     
    Exhibit
     
    Description
    10.1

    At the Market Offering Agreement, dated September 26, 2025, between the Company and H.C. Wainwright & Co., LLC
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL documents)


    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    SILEXION THERAPEUTICS CORP
     
     
    Date: September 26, 2025
    By: /s/ Ilan Hadar
     
    Name:
    Ilan Hadar
     
    Title:
    Chief Executive Officer


    Get the next $SLXN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLXN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SLXN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Peled Amnon claimed no ownership of stock in the company (SEC Form 3)

    3 - Silexion Therapeutics Corp (0002022416) (Issuer)

    12/18/24 6:00:43 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SLXN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SLXN
    SEC Filings

    View All

    Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

    New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence of gastric cancer activity expands potential therapeutic reach of SIL204 GRAND CAYMAN, Cayman Islands, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that SIL204 has demonstrated activity against eleven human cell lines originating from 5 different organ cancer sites, each with a specific  KRAS mutation. Hi

    9/30/25 8:40:00 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

    GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with both Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), concerning the minimum bid price and shareholders' equity requirements. The letter, dated September 23, 2025, confirmed that the Company has successfully met the minimum bid price requirement of $1.00 per share. Additionally, Nasdaq conf

    9/25/25 8:45:00 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

    Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion Therapeutics" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of  1,500,000 of the Company's ordinary shares (or ordinary share equivalents), series A warrants to purchase up to  1,500,000 ordinary shares and series B warrants to purchase up to 1,500,000 ordinary shares at a combined public offering price of $4.00 per share (or per ordinary share equivalent) and accompanying warrants. The series A warrants will have an exercise price of $4.00 per share, will be

    9/11/25 9:16:47 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Silexion Therapeutics Corp

    EFFECT - Silexion Therapeutics Corp (0002022416) (Filer)

    10/1/25 12:15:29 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Silexion Therapeutics Corp (0002022416) (Filer)

    9/30/25 9:05:56 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Silexion Therapeutics Corp

    S-3 - Silexion Therapeutics Corp (0002022416) (Filer)

    9/26/25 4:30:57 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SLXN
    Financials

    Live finance-specific insights

    View All

    Silexion Therapeutics Announces 1-for-15 Reverse Share Split

    Grand Cayman, Cayman Islands, July 16, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-15 reverse share split of its ordinary shares. The reverse share split will become effective after market close on July 28, 2025, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at market open on July 29, 2025, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every

    7/16/25 8:44:00 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Announces 1-for-9 Reverse Share Split

    GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-9 reverse share split of its ordinary shares. The reverse share split will become effective after market close on November 27, 2024, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Global Market at market open on November 29, 2024, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every nine ordinary shares of

    11/22/24 4:30:00 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SLXN
    Leadership Updates

    Live Leadership Updates

    View All

    Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

    Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company's audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing nov

    12/10/24 8:30:00 AM ET
    $BLRX
    $SLXN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SLXN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Silexion Therapeutics Corp

    SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

    11/20/24 6:15:12 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Silexion Therapeutics Corp

    SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

    8/22/24 6:44:28 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Silexion Therapeutics Corp

    SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

    8/22/24 5:23:46 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care